The JAK-STAT Signaling Pathway in Immunity and Autoimmune Diseases
The JAK-STAT Signaling Pathway
The JAK–STAT signaling pathway serves as a central conduit for signaling by numerous
cytokines and interferons, playing a critical role in hematopoietic cell
differentiation, immune homeostasis, and the development of select inflammatory and
neoplastic disorders. Dysregulated JAK–STAT signaling underlies a range of autoimmune
diseases, hematologic malignancies, and chronic inflammatory conditions, making this
pathway an important therapeutic target[2].
The activation of the classic JAK-STAT signaling pathway mainly involves the following
five steps[3].
I Ligand binding: The ligand (e.g., cytokines or growth factors) binds to its
corresponding receptor on the cell surface, inducing receptor dimerization and
recruitment of associated JAKs.
II Activation of JAKs: JAKs are constitutively bound to the cytoplasmic domain of
the receptor. When the ligand binds to the receptor, JAKs undergo transphosphorylation,
leading to tyrosine phosphorylation of the receptor and creation of docking sites for
STAT proteins.
III STAT phosphorylation: Activated JAKs phosphorylate tyrosine residues on the
receptor, forming a structure called "phosphotyrosine residue". This structure can be
recognized by the SH2 domains of STAT proteins, which are then phosphorylated by JAKs.
IV STAT activation and dimerization: Phosphorylated STATs detach from the
receptor and form homodimers or heterodimers via reciprocal SH2-phosphotyrosine
interactions.
V Transcriptional activation: STAT dimers translocate into the nucleus, where
they bind to specific DNA sequences and modulate the transcription of target genes.
To maintain signaling fidelity and prevent excessive activation, several negative
regulators such as protein inhibitor of activated STAT (PIAS), suppressor of cytokine
signaling (SOCS)/cytokine-inducible SH2-containing protein (CIS) family members, and
protein tyrosine phosphatases (PTPs) are engaged: PIAS
inhibits STAT-DNA binding; CIS/SOCS proteins prevent STAT recruitment to the receptor,
inhibit JAK activity, or target JAK/STAT for degradation; and PTPs—such as
CD45—dephosphorylate STAT dimers, JAKs, or receptor subunits
(Fig. 1).
Figure 1. Activation and negative regulation of the classical JAK-STAT signaling
pathway[3].
Role of JAK-STAT Signaling in Immune Regulation and Autoimmune Diseases
The JAK-STAT signaling pathway serves as a critical conduit for cytokine-mediated immune
regulation, orchestrating the differentiation, development, and function of multiple
immune cell subsets.
Distinct cytokines activate specific STAT proteins, thereby guiding lineage decisions
and effector programs. For example,
IL-12 activates STAT4
to promote Th1 differentiation, which contributes to pro-inflammatory responses in
autoimmune conditions such as
rheumatoid arthritis (RA)
and
psoriasis.
IL-4
signals via
STAT6 to induce Th2 responses, often
implicated in allergic diseases like
atopic dermatitis
(AD).
IL-6 and
IL-23 activate
STAT3 to drive
Th17 cell differentiation and
IL-17 production, key
mediators in chronic tissue inflammation. Conversely,
IL-2 signaling through
STAT5
supports the development of regulatory T cells (Tregs), promoting immune tolerance and
homeostasis.
Figure 2. The JAK-STAT signaling pathway and immune[4].
Together, these cytokines tightly regulate the differentiation and function of immune
cells, contributing to the development of either protective immune responses or chronic
inflammatory diseases.
Clinical Applications of JAK Inhibitors and Cytokine-Targeted Antibodies
The JAK-STAT signaling pathway plays a central role in the pathogenesis of both
autoimmune diseases and cancer. Therapeutic modulation of this pathway has demonstrated
the ability to suppress tumor growth, metastasis, and angiogenesis in oncology, while
also reducing inflammation and aberrant immune activation in autoimmune conditions.
Various treatment strategies have been developed, including JAK inhibitors, cytokine- or
receptor-targeting antibodies,
STAT inhibitors, and
emerging modalities such as peptide-based agents,
oligonucleotides, and
small
interfering RNAs (siRNAs).
Figure 3. Therapeutic targets of the JAK/STAT signaling pathway[3].
Among the diverse strategies targeting the JAK-STAT pathway, JAK inhibitors and
cytokine-targeted antibodies have emerged as the most clinically validated and widely
adopted modalities. They both aim to modulate dysregulated cytokine signaling to restore
immune homeostasis, but they differ significantly in their mechanisms of action,
molecular characteristics, and other key aspects. A comparative overview is presented in
Table 1.
Table 1. Comparison of JAK inhibitors and cytokine-targeted antibodies in modulating the
JAK-STAT pathway.
| Aspect |
JAK inhibitors |
Cytokine-targeted antibodies |
| Mechanism of Action |
Small-molecule inhibitors that enter cells and inhibit JAK kinases (JAK1, JAK2,
JAK3, TYK2) by
competing with ATP, disrupting downstream
STAT signaling. |
Monoclonal antibodies that bind to extracellular cytokines or their
receptors, blocking specific cytokine signaling pathways. |
| Molecular Size |
Small molecules (typically a few hundred daltons). |
Large molecules (typically over 100,000 daltons). |
| Route of Administration |
Oral or topical administration. |
Subcutaneous or intravenous injection. |
| Target Specificity |
Broad-spectrum inhibition of multiple cytokine pathways via JAK-STAT
signaling. |
High specificity for individual cytokines or cytokine receptors (e.g.,
IL-4Rα, TNF-α). |
| Advantages |
- Convenient oral dosing
- Potential to target multiple cytokines simultaneously |
- High specificity reduces off-target effects
- Well-established pharmacokinetics |
| Limitations |
- Risk of off-target effects (e.g., infections, cytopenias)
- Broader immunosuppression |
- Injectable route may reduce patient compliance
- Narrower target scope |
| Examples |
Tofacitinib, Baricitinib, Upadacitinib |
Secukinumab (anti-IL-17A),
Infliximab (anti-TNF-α),
Dupilumab (anti-IL-4Rα) |
In summary, JAK inhibitors and cytokine-targeted antibodies represent two distinct
approaches to JAK-STAT pathway modulation. In the following sections, we will delve into
their clinical applications in detail and highlight emerging trends shaping the future
of autoimmune disease treatment.
Clinical Applications of JAK Inhibitors
Table 2. Overview of clinical progress of JAK inhibitors (partial)[5].
| Drug |
Target |
Clinical phase |
Diseases |
| Tofacitinib (CP690550) |
JAK3>JAK1>>(JAK2) |
Approved |
RA, Psoriasis and PsA,
ulcerative colitis (UC),
juvenile idiopathic arthritis
|
| Phase II |
Alopecia areata (AA),
Crohn’s disease,
ankylosing spondylitis,
kidney transplant,
AD (topical)
|
| Baricitinib (INCB28050,
LY3009104) |
JAK1, JAK2 |
Approved |
RA |
| Phase II |
Graft-versus-host disease (GVHD), giant cell arteritis,
diabetic nephropathy
|
| Ruxolitinib (INC424) |
JAK1, JAK2 |
Approved |
Myeloproliferative neoplasms |
| Phase II/III |
Various cancers, GVHD |
| Phase II |
RA, Vitiligo, AA, psoriasis, AD (topical)
|
| Upadacitinib (ABT494) |
JAK1 |
Phase III |
RA |
| Phase II/III |
UC, Crohn’s disease |
| Phase II |
AD |
| Decernotinib (VX509) |
JAK3 |
Phase II/III |
RA |
| Filgotinib (GLPG0634) |
JAK1 |
Phase III |
RA |
| Phase II/III |
UC, Crohn’s disease |
JAK inhibitors have shown considerable therapeutic potential in treating inflammatory
autoimmune diseases. First-generation pan-JAK inhibitors, including
Tofacitinib,
Baricitinib, and
Ruxolitinib, are FDA-approved and widely used, but their
non-selective inhibition may result in off-target effects and safety concerns. In
response, second-generation inhibitors like
Upadacitinib
and
Decernotinib have been developed with increased
selectivity to improve safety profiles
[5]. However, enhanced selectivity may
compromise efficacy. Current research efforts focus on developing highly selective JAK
inhibitors, such as
SHR0302,
Abrocitinib, and
Delgocitinib, to
achieve an optimal balance between therapeutic efficacy and tolerability.
Figure 4. Effects of targeting different JAK isoforms[5].
This figure demonstrates the distinct effects of selectively targeting different JAK
isoforms (JAK1, JAK2, JAK3, and TYK2) on various cytokine signaling pathways. By
selectively inhibiting specific JAK isoforms, it becomes possible to precisely modulate
particular cytokine signals, thereby minimizing off-target effects and enhancing
therapeutic efficacy. For example, selective inhibition of JAK3 can reduce the activity
of cytokines such as IL-2 and IL-15, which are critical for immune cell activation,
while preserving other pathways essential for normal hematopoiesis and immune
homeostasis.
Clinical Applications of Cytokine-Targeted Antibodies
Cytokine-targeted antibodies have been extensively studied. For example, blockade of
IL-2, IL-12, IL-17, and TNF has been successfully used to treat chronic inflammatory
diseases such as RA, IBD, and psoriasis. Some of these blockades are market-approved,
such as anti-IL-2Ralpha, anti-IL-5, anti-IL-6, anti-IL-6R, anti-IL-12, and anti-IL-23.
The anti- IL-2Ralpha antibody, also known as
daclizumab,
markedly inhibited the phosphorylation of JAK1, JAK3, and STAT5a/b, thus significantly
decreasing transplant rejection.
Siltuximab is an IL-6
antagonist and has been approved for the treatment of idiopathic multicentric
Castleman's disease (iMCD).
Tocilizumab, an anti-IL-6R
humanized antibody, has been approved for the treatment of RA, cytokine release syndrome
(CRS), and iMCD
[6-8].
Cytokine-antibody fusion proteins represent an innovative biopharmaceutical class,
enhancing the therapeutic index of cytokine payloads by fusing specific antibodies with
cytokines or receptor antagonists. Examples include ch14.18-IL-2,
Hu14.18-IL-2, NHS-IL2LT, DI-Leu16-IL-2, BC1-IL-12, and
L19-TNF. These fusion proteins have proven effective in
treating chronic inflammatory diseases like RA, IBD, and psoriasis by targeting
cytokines such as IL-2, IL-12, IL-17, and TNF
[6-8].
Table 3. Some market-approved cytokine-targeted antibodies targeting JAK-STAT signaling
pathway[6-8].
| Drug |
Target |
Clinical phase |
Indication(s) |
| Siltuximab |
IL-6 |
Approved |
iMCD |
| Tocilizumab |
IL-6R |
Approved |
RA, CRS, iMCD |
| Mepolizumab |
IL-5 |
Approved |
Eosinophilic asthma, hypereosinophilic syndrome
(HES), eosinophilic granulomatosis with polyangiitis (EGPA) |
| Reslizumab |
IL-5 |
Approved |
Severe eosinophilic asthma |
| Benralizumab |
IL-5R |
Approved |
Severe eosinophilic asthma, EGPA |
| Ustekinumab |
IL-12/IL-23 (p40) |
Approved |
Plaque psoriasis, PsA, Crohn’s Disease |
| Dupilumab |
IL-4Rα |
Approved |
AD, asthma, chronic rhinosinusitis with nasal
polyps (CRSwNP), eosinophilic esophagitis
(EoE) |
The Future Landscape of Autoimmune Disease Treatment
Expanding the Target Spectrum
The therapeutic target landscape for autoimmune diseases has evolved substantially since
2020. Between 2020 and 2024, the number of agents under investigation increased from 131
to 193, encompassing 92 distinct therapeutic targets[1]. This growth reflects both
continued development within established cytokine and kinase families—such as the IL
family and JAK enzymes—and increased investment in emerging targets such as TL1A, OX40,
and TYK2.
Figure 5. Therapeutic targets in autoimmune disease: comparison of the top 15 targets
under investigation in 2020 and 2024[1].
Notably, Figure 5 highlights the continued prominence of the JAK family—including JAK1,
JAK2, JAK3, and the increasingly differentiated TYK2 isoform—as key intracellular kinase
targets in autoimmune diseases. In parallel, cytokine-related targets maintain a
dominant role, with expanded investigation into IL family members (e.g., IL-4, IL-5,
IL-13) and TNF superfamily components such as TL1A, OX40, and CD40.
Future Prospects
The
immunology drug development pipeline remains highly
dynamic, with several first-in-class therapies expected to reach the clinic in the
coming years. Novel agents targeting the OX40/OX40L axis (e.g.,
rocatinlimab,
amlitelimab) aim to
address upstream regulators of IL-4/IL-13 production in dermatology. In
chronic obstructive pulmonary disease (COPD), two competitive
candidates targeting IL-33—
itepekimab and the dual
IL-33/ST2 inhibitor
tozorakimab—represent an emerging
therapeutic class. Additionally, modulation of the CD40/CD40L axis may offer new
treatment options for systemic autoimmune diseases, including
dazodalibep for Sjögren’s syndrome and
dapirolizumab for lupus erythematosus. In gastrointestinal
disorders, three TL1A-targeted candidates (
tulisokibart,
RVT-3101,
duvakitug) are advancing clinical development in Crohn’s disease and UC.
First-in-class opportunities are also emerging for targets including IL-4, IL-33, IL-18,
IRAK4 (enabling pan-IL-1 family inhibition), and TSLP (a key upstream mediator of type 2 inflammation). Combination approaches (e.g., IL-17/TNF co-targeting, dual kinase inhibitors) and innovations in selectivity (IL-17A/F isoforms), dosing regimens (long-acting IL-5 inhibitors), and delivery methods (oral IL-17 inhibitors) are poised to broaden therapeutic options.
Competition is intensifying for first-to-market positions (TL1A, OX40, TSLP, IL-33, TYK2) and best-in-class agents (e.g., enhanced-selectivity IL-23/JAK inhibitors), particularly for type 2 inflammatory disorders. The field is increasingly moving toward complementary strategies that leverage common inflammatory pathways while addressing disease-specific pathophysiology. Key challenges include optimizing drug positioning, applying biomarker-driven patient stratification, and balancing the roles of oral small molecules versus injectable biologics. These trends mirror oncology’s evolution and herald a new era in autoimmune disease management.
Summary
The JAK-STAT signaling pathway plays a central role in autoimmune pathogenesis by regulating immune cell differentiation and function through cytokine signaling. JAK inhibitors and cytokine-targeted antibodies have emerged as the most clinically validated and widely adopted therapies targeting this pathway in autoimmune disease treatment.
As research advances, novel therapies targeting emerging pathways (e.g., OX40, TL1A) and combination strategies (e.g., dual kinase inhibitors) are expected to provide more personalized and effective treatment options. These innovations, coupled with ongoing improvements in patient stratification, are redefine the future landscape of autoimmune disease management.
Recommended Products
| Cat. No. |
Product Name |
Description |
| HY-40354 |
Tofacitinib |
An orally available JAK3/2/1 inhibitor |
| HY-15315 |
Baricitinib |
A selective and orally bioavailable JAK1 and JAK2 inhibitor |
| HY-50856 |
Ruxolitinib |
An orally active and selective JAK1/2 inhibitor |
| HY-12469 |
Decernotinib |
A potent, orally active JAK3 inhibitor |
| HY-18300 |
Filgotinib |
A selective, orally available JAK1 inhibitor |
| HY-19569 |
Upadacitinib |
A potent, orally active and selective JAK1 inhibitor |
| HY-112724 |
SHR0302 |
A potent and orally active inhibitor of all JAK family members, especially JAK1 |
| HY-107429 |
Abrocitinib |
A potent, orally active and selective JAK1 inhibitor |
| HY-109053 |
Delgocitinib |
A specific JAK inhibitor targeting JAK1, JAK2, JAK3, and TYK2 |
| HY-108738 |
Daclizumab |
A humanized monoclonal antibody blocking CD25 (IL-2 receptor α-subunit) |
| HY-P9956 |
Siltuximab |
An anti-IL-6 monoclonal antibody |
| HY-P9917 |
Tocilizumab |
An anti-IL-6 receptor neutralizing antibody |
| HY-P9916 |
Sarilumab |
A humanized monoclonal anti-IL-6Rα IgG1 antibody |
| HY-P99316 |
Sirukumab |
A humanized monoclonal anti-IL-6 IgG1 antibody |
| HY-P99012 |
Clazakizumab |
A monoclonal antibody targeting IL-6 cytokine |
| HY-P99210 |
Olokizumab |
A humanized monoclonal antibody targeting IL-6 |
| HY-P99385 |
Vobarilizumab |
A humanized bispecific anti-IL-6R and anti-albumin monoclonal antibody |
| HY-P99112 |
Satralizumab |
A humanized monoclonal IL-6 inhibitor |
| HY-P99168 |
Anifrolumab |
A human monoclonal antibody blocking type I interferon receptor |
| HY-P99191 |
Emapalumab |
A human monoclonal antibody inhibiting IFN-γ |
LinkedIn
Researchgate
Facebook
X
Instagram
Mail
The JAK-STAT Signaling Pathway in Immunity and
Autoimmune Diseases
Clinical Applications of JAK Inhibitors and
Cytokine-Targeted Antibodies
The Future Landscape of Autoimmune Disease
Therapy
